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Abstract 
Angiogenesis plays an important role in tumor progression.  Several reports have 
demonstrated that ADAMTS1 (a disintegrin and metalloproteinase with 
thrombospondin motifs1) inhibited angiogenesis via multiple mechanisms.  The aim of 
this study was to investigate the effect of ADAMTS1 on endothelial cells in vitro and on 
tumor growth with regard to angiogenesis in vivo.  We examined the effects of the 
transfection of ADAMTS1 using two constructs, full-length ADAMTS1 (full 
ADAMTS1) and catalytic domain-deleted ADAMTS1 (delta ADAMTS1).  
Transfection of both the full ADAMTS1 and delta ADAMTS1 gene constructs 
demonstrated the secretion of tagged-ADAMTS1 protein into the conditioned medium, 
so we examined the effects of ADAMTS1-containing conditioned medium on 
endothelial cells.  Both types of conditioned media inhibited endothelial tube 
formation, and this effect was completely abolished after immunoprecipitation of the 
secreted protein from the medium.  Both types of conditioned media also inhibited 
endothelial cell migration and proliferation.  We then examined the impact of 
ADAMTS1 on endothelial cell apoptosis.  Both conditioned media increased the 
number of Annexin V-positive endothelial cells and caspase-3 activity and this effect 
was attenuated when z-vad was added.  These results indicated that ADAMTS1 
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induced endothelial cell apoptosis.  We next examined the effects of ADAMTS1gene 
transfer into tumor-bearing mice.  Both full ADAMTS1 and delta ADAMTS1 
significantly inhibited the subcutaneous tumor growth.   Collectively, our results 
demonstrated that ADAMTS1 gene transfer inhibited angiogenesis in vitro and in vivo, 
likely as a result of the induction of endothelial cell apoptosis by ADAMTS1 that occurs 
independent of the protease activity. 
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Introduction 
Angiogenesis, the formation of new blood vessels from preexisting
 
capillaries, is 
observed under various pathophysiological conditions (e.g., wound healing, diabetic 
retinopathy and tumor growth)(1).  Neovascularization consists of endothelial cell 
migration, proliferation and new network formation.  Tumors require a substantial 
blood supply, and promote angiogenesis when they grow.  Avascular tumors have a 
severely restricted growth potential.  As a result, anti-angiogenic treatments are thus 
considered to be potentially useful for cancer therapy (2, 3).  To date, many 
anti-angiogenic therapies have been designed to inhibit tumor growth as well as cancer 
cell dissemination (4, 5).   
A disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) is a 
newly categorized matrix metalloproteinase (MMP), which has multiple domains, 
including propeptide, metalloproteinase, disintegrin-like and spacer-region domains, 
and domains containing thrombospondin (TSP-1) type Ι motifs (6).  ADAMTSs have 
diverse functions, such as pro-collagen processing (7) and cleavage of Von Willebrand 
factor (8, 9).  One of the best characterized biological functions of ADAMTS is 
proteolytic activity against extracellular matrix proteins, including proteoglycans 
(10-13).   
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ADAMTS1 is the first member of the ADAMTS family that was identified, and 
has been shown to degrade extracellular matrix proteins such as versican and aggrecan 
(11, 14).  The recombinant ADAMTS1 protein has anti-angiogenic properties(15). 
These reports supported the observed inhibitory effect of ADAMTS1 on endothelial cell 
growth and angiogenesis; however, whether ADAMTS1 inhibits tumor progression 
remains controversial (16-19).  Accordingly, we investigated the effect of ADAMTS1 
on both endothelial cell apoptosis and tumor growth using two different constructs, a 
full-length ADAMTS1 and a metalloproteinase-deleted ADAMTS1. 
 
Materials and Methods 
ADAMTS1 expression construct and catalytic domain deletion construct  
The sequence encoding ADAMTS1 was amplified by polymerase chain reaction 
(PCR) using the KIAA1344 plasmid (Kazusa DNA Institute, Chiba, Japan) as a 
template.  We designed to fuse ADAMTS1 to the COOH-terminal v5 epitope tag 
present in the expression vector (pcDNA/v5-D-TOPO; Invitrogen, Carlsbad, CA, USA) 
and this construct was designated “full ADAMTS1”.  The signal peptide and FLAG 
epitope tag containing a mammalian expression vector with the CMV promoter was a 
kind gift from Dr. Billy G. Hudson and Dr. Vadim Pedchenko (20).  The catalytic 
OBIKA et al 
Apoptosis and tumor inhibition by ADAMTS1 
-7- 
domain deletion construct of ADAMTS1 cDNA with the FLAG epitope tag (delta 
ADAMTS1) was generated as detailed in Fig. 1.  The sequence of each construct was 
determined to confirm that no amino acid mutations had been caused by the PCR 
reaction prior to the study.  
Cell lines and cultures 
Human umbilical vein endothelial cells (HUVEC) were purchased from Kurabo 
(Osaka, Japan) and cultured in HuMedia-EBM2 (Kurabo) with a kit containing 2% fetal 
bovine serum (FBS), growth factors, 100 U/mL penicillin, and 100 μg/mL streptomycin, 
as previously described (5).  COS-7 cells were purchased from ECACC (Dainippon 
Sumitomo Pharmaceutical Co., Osaka, Japan).  Rat smooth muscle cells (SMC) and 
human skin fibroblasts (HSF) were obtained as previously reported (5).  Human 
fibrosarcoma HT1080 cells, human prostate cancer DU145 cells, and Chinese hamster 
ovarian (CHO)-K1 cells, were purchased from the American Type Culture Collection 
(ATCC, Rockville, MD, USA).  Cells at passage 3-6 were used for all experiments.  
The SMC, HSF, HT1080, DU145 and CHO-K1 cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) with 10% FBS, 100 U/mL penicillin, and 100 
μg/mL streptomycin.  Cells were cultured at 37°C under 5% CO2 and 20% O2 in a 
humidified chamber. 
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Transfection and preparation of conditioned media 
Transient transfection was performed as previously described (5, 21) with slight 
modifications.  For the COS-7 cells, lipofectamine 2000 (Invitrogen) was used for 
transfection according to the manufacturer’s protocol.  We renewed the 
DNA-containing medium six hours and twenty-four hours after transfection.  After 
forty-eight hours, the medium was changed, and we collected the conditioned medium 
after seventy-two hours.   
The cells were washed with phosphate-buffered saline (PBS) twice, and then 
proteins were extracted with cell lysis buffer as previously reported (22, 23).  
Alternatively, the produced tagged protein was depleted from the conditioned medium 
by immunoprecipitation of the tagged protein with either an anti-v5 or anti-FLAG M2 
affinity gel (Sigma, St. Louis, MO, USA) as previously described (5).  Briefly, 
conditioned media was incubated with affinity gel for overnight at 4°C.  Supernatant 
after centrifugation, in which tagged-protein was no longer detectable, was used as 
“conditioned medium post-IP” in further experiments.   For the transient transfection 
for the HUVEC, electroporation with microporator (BMS-MP-100; Microporator, Seoul, 
Korea) was performed as previously described (24).   Briefly, cells were removed 
from the plate with trypsin, centrifuged, and dissolved in serum-free medium.  Cell 
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and constructs were mixed into the buffer and incubated for 5m on ice, then expose to 
electricity (1000V 30mS, 2-pulse).  Cells were plated at a density of 1.0 × 10
5
 cells in 
96-well dishes with 100 µL culture medium without antibiotics.  After seeding, cells 
were allowed
 
to recover for 24h.  The medium was then changed and cells were used 
for the analysis. 
 
Western blot analysis and antibodies 
The expression of full ADAMTS1 and delta ADAMTS1 was examined by a 
Western blot analysis, as described previously.(21, 25)  Briefly, 20 l of each sample 
was mixed with 6×
 
Laemmli sample buffer (60 mM Tris-HCl (pH 6.8), 2% SDS, 5% 
mercaptoethanol,
 
10% glycerol) and subjected to sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).  After electrophoresis, 
proteins were transferred to PVDF membranes (Advantech, Tokyo, Japan) using 
transfer buffer, and then the membranes were blocked for 1 h in 5% nonfat dried milk in 
PBS.  The membranes were hybridized at room temperature (RT) for 1 h with a mouse 
anti-v5 antibody (Invitrogen) or an anti-FLAG M2 monoclonal antibody (Sigma).  
After stringent washing with PBS containing 0.05% Tween 20 (PBS-T) three times for 5 
minutes each at RT, the membranes were incubated with the appropriate secondary 
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antibodies (ICN Pharmaceuticals, Aurora, OH, USA).  Following three successive 
washes with PBS-T, immunoreactive bands were visualized using the enhanced 
chemiluminescence system (ECL; Amersham Bioscience, Piscataway, NJ, USA).   
 
Endothelial tube formation assay 
The endothelial tube formation assay was performed as previously described (5).  
Briefly, 100 μL of Matrigel (Becton Dickinson, Franklin Lakes, NJ, USA) was applied 
to 96-well plates, and a suspension of 7.5 × 10
3
 of HUVEC in 50 μL EBM2 was seeded 
into each well, and then 50 μL of each conditioned medium (n=12 each) was added per 
well.  The cells were incubated for 24 h at 37°C and viewed using an IX71 microscope 
(Olympus).  The length of tube formations per well (magnification at 40 ×) was 
measured using the Scion Image software program by two investigators blinded to the 
experimental protocols, and the recorded lengths were averaged.  
 
Cell migration assays 
The HUVEC migration was assayed as described previously (5, 26).  In brief, 
confluent cells in 48-well plates were scratched with a sterile pipette tip.  The cells 
were washed twice with EBM2 to remove cellular debris.  After removal of the 
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cellular debris, 100 μL EBM2 with 2% FBS and 100 μL of each conditioned medium 
were added to each well.  The HUVEC were then incubated at 37°C for 24 h.  The 
cell migration assays were also performed for SMC, HSF and CHO-K1 cells using the 
same method. After 24 h in culture, the cells were fixed.  The cells that had migrated 
into the denuded area were photographed with a CCD camera and counted with the 
Scion Image software program. 
 
Cell proliferation assays 
Cell proliferation was examined using a CellTiter AQueous One Solution Cell 
Proliferation Assay kit (Promega, Madison, WI, USA) according to the manufacturer’s 
instructions.  Briefly, a suspension of HUVEC, SMC, HSF and CHO-K1 cells (1 × 10
4
 
cells/well, passage 3–5) in 50 μL EBM2 with 2% FBS was added to 96-well plates, and 
supplemented with 50 μL of each conditioned medium.  After incubation for 24 h or 
the time indicated, the cell viability was measured as described (27, 28).  Z-vad 
(Peptide Institute Inc, Osaka, Japan) was used to examine whether caspase is involved 
in this affect.  All samples were read in triplicate.   
 
Flow cytometric analysis 
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An Annexin V Assay Kit (MBL, Nagoya, Japan) was used according to the 
manufacturer’s instructions.  Briefly, HUVEC, SMC, HSF and CHO-K1 cells (5 × 105 
cells/well) were seeded into 6-well plates in 2 mL EBM2 with 2% FBS.  The following 
day, the medium was changed to 1 mL fresh medium containing 2% FBS plus 1 mL 
conditioned medium.  After 24 h in culture, the attached cells were trypsinized and 
centrifuged at 3000×g for 5 min at 4°C.  The cells were then washed in PBS and 
resuspended in binding buffer (10 mM HEPES/NaOH pH 7.4, 140 mM NaCl, 2.5 mM 
CaCl2).   Five microliters of Annexin V conjugated with biotin and propidium iodide 
were added, and the cells were incubated in a darkroom for 15 min.  The cells were 
washed again in PBS and then were resuspended in binding buffer.  After 
centrifugation at 3000 ×  g for 5 min at 4°C, the cells were fixed with 2% 
formaldehyde and washed with PBS.  After centrifugation again, the cells were 
washed with PBS, and streptavidin-conjugated FITC (DAKO, Glostrup, Denmark) was 
added, followed by incubation for 15 min at RT.  The cells were then washed with PBS 
again and resuspended in 300 μL PBS.  Annexin V-FITC-labeled cells were counted 
using a FACScaliber flow cytometer (Becton Dickinson).  The data were then analyzed 
using the Cell Quest software program (Becton Dickinson). 
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Caspase3/7 assay 
The caspase 3/7 activity levels were measured using an assay kit 
(Caspase-Glo3/7 Assay; Promega) according to the manufacturer’s instructions.  
Briefly, HUVEC (1 × 10
4 
/well) were seeded into 96-well plates in 100 μL EBM2 with 
2% FBS.  The following day, the medium was removed, and 50 μL fresh EBM2 
containing 2% FBS plus 50 μL conditioned medium was added.  After a 24 h culture, 
the caspase 3/7 activities were measured using a plate-reading luminometer (Dainippon 
Sumitomo Pharma. Co., Osaka, Japan). 
 
In vivo tumor studies 
All protocols involving experimental animals followed the local institutional 
guidelines for animal care, which are comparable to those described in the “Guide for 
the Care and Use of Laboratory Animals” published by the Institute for Laboratory 
Animal Research (National Institutes of Health Publication No. 85-23, revised 1996).  
HT1080, DU145 and CHO-K1 cells (1.0×106 cells in 50 μL serum-free DMEM and 50 
μL Matrigel) were inoculated subcutaneously into the right flank of 5- to 7-week-old 
male BALB/c nude mice (Charles River Japan)(five mice per treatment group) and each 
tumor growth was monitored with Vernier calipers everyday, as described previously 
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(29).  The volume was calculated according to the formula (volume = length × width
2 
× 0.52).(5, 30)  When the tumors reached a mean volume of 30–60 mm3, treatment 
was initiated.  The full ADAMTS1 cDNA-containing plasmid (10 μg) or delta 
ADAMTS1 cDNA-containing plasmid (10 μg) was mixed with 10 μL cationic lipid 
(DMRIEC; Invitrogen) and then dissolved in 100 μL OPTIMEM-1 (Gibco).  
Approximately 20 μL of the mixture was then directly injected into the tumor every 24 
h for 7 days.  The CMV/FLAG empty vector (10 μg) was used as a negative control.  
Mice were sacrificed by cervical dislocation the day after the final treatment.  The 
tumors were removed, snap frozen in liquid
 
N2, and embedded in OCT compound 
(Sakura, Tokyo, Japan).   
 
Immunohistochemical staining 
Frozen sections (8 μm) were placed on silane-coated glass slides (DakoCytomation, 
Kyoto, Japan) for histological studies, as previously described (31).  Blood vessels 
were detected by immunohistological staining using an anti-CD31 antibody (used at 
1:100 dilution) (BD Pharmingen, Franklin Lakes, NJ, USA).  Immunoperoxidase 
staining was carried out using a VECTASTAIN ABC Kit (Vector Laboratories, 
Burlingame, CA, USA).  The number of the vessels in the tumors was measured as 
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described previously (32).  Anti-Cleaved Caspase-3 (Asp175) antibody (used at 1:100 
dilution) (Cell Signaling Technology, Danvers, MA, USA) and anti-CD31 antibody 
were used for immunofluorescent staining as previously described (33).  The tumor 
section was incubated with two antibodies for overnight at 4°C and then incubated with 
the secondary antibodies (Alexa Fluor 488-conjugated anti-rabbit IgG and 
Cy3-conjugated anti-rat IgG, respectively) at appropriate dilution.  The 
immunofluorescent signals were observed with an LSM510 confocal microscope (Carl 
Zeiss) at the Central Research Laboratory, Okayama University Medical School.  All 
images were processed using Adobe Photoshop CS2.  All experiments were repeated 
using three animals, which we obtained similar results. 
 
Statistical analysis 
The statistical analysis was performed using the unpaired Student’s t-test.  P < 
0.05 was considered to be significant. 
 
Results 
Expression of human ADAMTS1 and its fragments 
We designed two constructs, full-length ADAMTS1 with a C-terminal v5-tag 
(full ADAMTS1) and a catalytic domain-deleted construct (delta ADAMTS1) (Fig. 1A).  
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We first transfected these constructs into COS-7 cells and collected the conditioned 
medium 72 h after transfection.  The fusion proteins with full ADAMTS1 and delta 
ADAMTS1 were detected by a Western blot analysis (Figs. 1B and C, respectively).  
Transiently produced proteins from both constructs were detected in the conditioned 
medium, as well as in cell extracts, in our system.  Full ADAMTS1 transfectants 
showed three major bands in conditioned medium that consisted of the unprocessed 
form of ADAMTS1 and its processed forms (Fig. 1B).  The lowest band (~22 kDa) 
was considered to be a proteolytic C-terminal fragment based on a previous reported 
(34).  The protein in the delta ADAMTS1-transfected conditioned medium was 
detected as a single band in conditioned medium and cell extracts (Fig. 1C).   
 
Effect of the conditioned medium on endothelial tube formation   
To test the effects of the transfected cell conditioned medium on endothelial cell 
tube formation, HUVEC were cultured on Matrigel in a mixture of fresh EB2 and 
conditioned medium, as described in the Materials and Methods.  Representative 
results of the endothelial tube formation assay are shown in Fig. 2; both types of 
conditioned media significantly inhibited the tube formation of HUVEC compared with 
the control (Figs. 2A, C).  These results indicated that both types of conditioned 
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medium contained factors that effectively inhibited the endothelial cell tube formation.  
When we depleted v5- or FLAG-tagged fragments from the conditioned medium by 
immunoprecipitation with an anti-v5 or an anti-FLAG agarose affinity gel, the 
inhibitory effects on tube formation were abolished (Figs. 2B, D, F).  These results 
indicate that the effects of the conditioned media were due to the tagged proteins.   
 
Inhibition of endothelial cell migration by ADAMTS1 
The effects of ADAMTS1-transfected conditioned medium on the migration of 
HUVEC are shown in Figure 3A.  Both types of conditioned media inhibited the 
migration of HUVEC, while the control (conditioned media from cells transfected with 
the empty vector) showed no effect on HUVEC migration.  This inhibitory effect on 
migration appeared to be specific to endothelial cells, because neither type of 
conditioned medium affected the migration of SMC, HSF or CHO-K1 cells compared to 
the control conditioned medium (Fig. 3B). 
 
Effects of ADAMTS1 on endothelial cell proliferation 
We next examined the effects of the conditioned medium from 
ADAMTS1-transfected cells on endothelial cell proliferation; both types of conditioned 
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media inhibited HUVEC proliferation.  As shown in Figure 4A-D, ADAMTS1 
inhibited the cell proliferation of HUVEC, but not SMC, HSF or CHO-K1 cells.  This 
effect was attenuated when Z-VAD (a specific inhibitor of caspases) was added to the 
conditioned medium, indicating that this effect was mediated by caspases (Fig. 4E).  
Both types of conditioned media inhibited endothelial cell attachment to collagen I and 
laminin (supplemental Fig. 1).    We further examined the effect of electroporation of 
ADAMTS1 on HUVEC proliferation.  As shown in Fig. 4F, both full and delta 
ADAMTS1 inhibited endothelial cell proliferation.   
 
Apoptotic effects of ADAMTS1 on endothelial cells 
To evaluate the apoptotic effects of ADAMTS1, we examined the Annexin V 
expression and caspase 3/7 activity.  We found that the number of Annexin-positive 
HUVEC was increased by both types of conditioned media compared to the control 
(Figs. 5A, B).  Interestingly, both the full ADAMTS1 and delta ADAMTS1 constructs 
caused a distinct shift of the peak of Annexin V fluorescence after 24 h of co-incubation 
only in endothelial cells, not in other types of cells, such as SMC, HSF and cancer cells 
(CHO-K1 cells) (Figs. 5A, B).  Furthermore, both full ADAMTS1 and delta 
ADAMTS1 increased the caspase 3/7 activity compared with the control vector-treated 
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HUVEC (Fig. 5C).  We also examined the effect of endothelial cell attachment 
incubated with each conditioned medium on extracellular matrix-coated plates. As 
shown in supplemental figure 1A-C, both conditioned media attenuated HUVEC 
attachment on type I collagen and laminin, but not on fibronectin.  
Effects of ADAMTS1 and its deletion construct on tumor growth and angiogenesis 
To assess the effects of ADAMTS1 gene therapy on tumor growth, HT1080, 
DU145 and CHO-K1 cells were inoculated subcutaneously into nude mice.  After the 
establishment of subcutaneous tumors, plasmids in DMRIEC were directly injected into 
tumors every 24 h for 7 days.  An empty vector was used as a negative control.  On 
the 8th day after starting the gene transfer, both the full ADAMTS1 and delta 
ADAMTS1 constructs significantly had suppressed the growth of subcutaneous tumors 
compared with the control (Figs. 6A-F).  We then examined the vessel distribution in 
tumors transfected with full ADAMTS1 (Fig. 7A) and delta ADAMTS1 (Fig. 7B), and 
compared them with cells treated with the empty vector (Fig. 7C) using an anti-CD31 
antibody.  The empty vector-treated implanted tumors were abundant in vessel 
formation, but the vessel formation was significantly decreased in tumors treated with 
the full ADAMTS1 or delta ADAMTS1 construct (Fig. 7D).  Next we examined the 
apoptotic effect on the tumor vasculature by ADAMTS1.  As shown in Fig. 7E-G, the 
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cleaved-caspase signals were observed in the tumor vasculature in the delta 
ADAMTS1-treated mice.  On the other hand, few signals for cleaved-caspase were 
observed in the control mice (Fig. 7H), indicating that ADAMTS1 gene transfer induced 
apoptosis in the tumor vasculature in vivo.   We also examined the transduced protein 
in tumor tissues.  As shown in supplemental figure 2A-C, immunopositive signals for 
both ADAMTS1 and delta ADAMTS1 were detectable, while there was no signal in 
tumors treated with the empty vector (supplemental Figure 2D).  These results 
indicated that this tumor does not produce detectable levels of ADAMTS1, and that 
tumor growth could be reduced by ADAMTS1 gene transduction.  
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Discussion   
In the present study, we demonstrated that ADAMTS1 inhibited angiogenesis in 
vitro and in vivo, which suggested that ADAMTS1 induces endothelial cell apoptosis.  
These inhibitory effects of ADAMTS1 could be achieved independently of its 
proteolytic activity. 
The anti-angiogenic properties of ADAMTS1 have been recently described.  
One of the most interesting properties of the gene is that it is located on chromosome 21, 
the locus for Down’s syndrome.  Reynolds et al., reported that tumor angiogenesis is 
inhibited in a mouse model of Down’s syndrome that has three copies of the ADAMTS1 
gene (19).  Several reports have suggested that the proteolytic activity of the protein is 
key to its activity.  For instance, ADAMTS1 cleaves large TSP1, and cleaved TSP-1 
demonstrates anti-angiogenic activity (13).  Iruela-Arispe et al. reported that 
ADAMTS1 binds to the VEGF receptor, which requires protease-mediated activation 
(35).  On the other hand, Fu et al., reported that the proteolytic fragment of versican 
produced by ADAMTS1 induced pathological angiogenesis (36).  In addition, 
ADAMTS1 null mice demonstrated delayed lymphangiogenesis, thus indicating that 
ADAMTS1 plays a role in lymphangiogenesis (37).  Interestingly, Luque et al. 
reported that the C-terminal half of ADAMTS1 binds to VEGF and affects VEGFR2 
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phosphorylation and endothelial
 
cell proliferation (38).  Rodriguez-Manzaneque et al. 
reported that deletion of the last two TSP1 motifs reduced the suppression of endothelial 
cell proliferation (34).  Together, these data indicate that the role of ADAMTS1 in 
angiogenesis is diverse, and that further studies are needed to clarify the numerous roles 
of the protein.  Our present results also demonstrated that the inhibitory effects of 
ADAMTS1 on endothelial cells is protease activity-independent.  We thus confirmed 
that ADAMTS1 has inhibitory effects on endothelial cells via a proteolytic 
activity-independent mechanism, and we suggest that the C-terminal half of ADAMTS1 
has a crucial role in this activity.   
We herein demonstrated that ADAMTS1 plays a role in apoptosis in endothelial 
cells in vitro and in vivo.  As reported for other anti-angiogenic molecules, such as 
TSP-1 (39, 40), ADAMTS1 induced apoptotic changes in endothelial cells, as indicated 
by the detection of Annexin V expression and increased caspase 3/7 activity (Fig. 5C).  
Furthermore, z-vad attenuated the effect of ADAMTS1, indicating the involvement of 
caspase signaling (Fig. 4E).  This effect was observed with both constructs, indicating 
that the proteolytic activity is not required for this effect.  It should be noted that 
ADAMTS1 did not affect the viability of CHO-K1 cells, but did inhibit the growth of 
tumors resulting from implanted CHO-K1 cells.  Interestingly, the inhibition of 
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proliferation was observed in endothelial cells, but not in other types of cells, including 
smooth muscle cells, fibroblasts and CHO-K1 cells.  ADAMTS1 also induced 
apoptosis in endothelial cells, but not in CHO-K1 cells, as indicated by the changes in 
Annexin V expression.  We therefore believe that the tumor inhibition, which was 
accompanied by a decrease in vessel density, that was induced by ADAMTS1 was 
largely due to the effect of the protein on endothelial cell apoptosis.   
There is a limitation of this study.  It is not clear whether there are specific 
receptor(s) for ADAMTS1 on endothelial cells.  As shown in this study, ADAMTS1 
attenuated endothelial cell attachment (supplemental Fig. 1), suggesting that ADAMTS1 
induced anoikis on endothelial cells.  Because of multiple functions of ADAMTS1 on 
inhibiting endothelial cells, apoptotic effect by ADAMTS1 is complex and we suggest 
that anoikis may be a part of this effect. 
In summary, we demonstrated the anti-tumorigenic effect by ADAMTS1 gene 
transfer that is accompanied by the inhibition of tumor angiogenesis.   
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Figure legends 
Figure 1. (A) Demonstration of the domain structure of full ADAMTS1 and its deletion 
construct used in the experiments.  (B) Cell lysates (lane 1) and conditioned medium 
(lane 2) derived from full ADAMTS1 transfectants were analyzed.  The cell lysates 
contained pro-ADAMTS1 protein (arrow), and conditioned medium contained two 
additional proteins (arrowheads).  The arrowheads indicate mature ADAMTS1 and 
C-terminal fragment ADAMTS1 produced by its autocatalytic activity, as previously 
reported.  (C) The cell lysates (lane 1) from delta ADAMTS1 transfectants and 
conditioned medium (lane 2) derived from delta ADAMTS1 transfectants. 
 
Figure 2.   The tube formation assay was carried out with conditioned medium.  The 
conditioned medium obtained from full ADAMTS1-transfected cells before 
immunoprecipitation (A) and post-immunoprecipitation (B).  The conditioned medium 
obtained from delta ADAMTS1-transfected cells before immunoprecipitation (C).  
The conditioned medium obtained from delta ADAMTS1-transfected cells 
post-immunoprecipitation (D) or from the control (E).  (F) The length of tube branches 
in the lower field was measured.  * indicates p<0.05.  Each column represents the 
mean ± SD.  
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Figure 3.   (A) The endothelial cells were incubated with conditioned medium and 
cell migration was monitored.  (B) The inhibitory effect of each conditioned medium 
on cell migration was compared.   Each column represents the mean ± SD of triplicate 
samples.  * indicates p<0.05 vs. control.  NS indicates that two groups were not 
significantly different.   
  
Figure 4.  The inhibition of cell proliferation by transfected-conditioned medium was 
monitored (A, HUVEC; B, SMC; C, HSF; D, CHO-K1).  * indicates p<0.05 vs. 
control.  NS indicates that two groups were not significantly different.  (E) The 
inhibitory effect of HUVEC proliferation by each conditioned medium was compared in 
the absence or the presence of Z-vad.  * indicates p<0.05.  (F) The inhibition of 
endothelial cell proliferation by electroporation with each construct was examined.  * 
indicates p<0.05 vs. control.  Each column represents the mean ± SD of triplicate 
samples.   
 
Figure 5.  (A) The Annexin V expression was examined by FACS analysis.  (B) The 
numbers of Annexin V-positive cells after treatment with the conditioned medium 
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obtained from both full ADAMTS1 (full) and delta ADAMTS1 (delta)-treated cells 
were compared with those after treatment with conditioned media obtained from control 
cells (control).  *indicates p<0.05 vs. control.  NS indicates that two groups were not 
significantly different.  (C) The caspase 3/7 activities in HUVEC treated with control 
medium were considered to be 100%.  * indicates p<0.05 vs. control. 
 
Figure 6.   In the left column (A, C and E), the size of tumors was monitored every 
day until day 8 (mean ± SE; n=5).  In the right column, the size of tumors on day 8 
was compared with those in the control group (B, D and F).  The size of each tumor on 
day 1 was considered to be 100% (A and B, HT1080; C and D, DU145; E and F, 
CHO-K1.).  * indicates p<0.05 vs. control.      
 
Figure 7.  The vessel formation was examined by immunohistochemistry ((A), 
full-ADAMTS1; (B), delta ADAMTS1; (C), empty vector).  The number of blood 
vessels was counted (D).  * indicates p<0.05 vs. control.  The apoptotic signals were 
observed in the ADAMTS1-treated tumor vasculature (E-G).  Sections of the tumor in 
delta ADAMTS1-injected mice were doubly stained with anti-CD31 antibody (Cy3; E) 
and anti-Cleaved caspase-3 antibody (FITC; F).  (G) Merged images obtained with 
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anti-CD31 antibody (Cy3) and anti-Cleaved caspase-3 antibody (FITC).  Arrows 
indicate the caspase-3-positive signals observed in the tumor vasculature.  In contrast, 
sections of tumors injected with empty vector showed only negligible FITC signals 
(green) whereas Cy3 signals (red) were more abundant than in panel G.  Scale bar in 
each panel represents 50 m. 
 
Supplemental Figure 1.  Inhibition of endothelial attachment by ADAMTS1.  
Supplemental figure 2.  Distribution of ADAMTS1 gene transfer into tumors. 
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Supplemental experiments: 
 Attachment assay 
For adhesion assay, extracellular matrix protein (collagen I, laminin, and 
fibronectin and poly-D-Lysine) coated 96-well plates (BD Pharmingen) 
were used.  HUVEC (1.0 × 104 cells) were suspended in 1:1 mixture of 
EBM2 and conditioned media, respectively, and incubated on each plate 
for 30 min.  The medium was aspirated and the adherent cells were 
washed with PBS for three times, and cells were fixed with 2% PFA.  
Then the cells were washed and stained with 0.2% crystal violet for 
5min.  Stained cells were dissolved in 500 μL of 1% SDS and the 
absorbance at 570nm was measured by microplate reader.    
  
Figure legends 
Supplemental Figure 1 
Inhibition of endothelial attachment by ADAMTS1. The numbers of 
attached endothelial cells were measured in each coated plates (A: 
collagen I, B: laminin, C: fibronectin). The absorbance of attached 
HUVEC suspended in the empty vector-conditioned media was counted 
as 100% and the absorbance were shown as relative value.  * indicates 
p<0.05 vs. control.  NS indicates that two groups were not significantly 
different. 
  
Supplemental Figure 2 
Distribution of ADAMTS1 gene transfer into tumors.  ADAMTS1 
distribution in the tumor tissue after gene transfer was examined by 
immunohistochemistry.  (A), ADAMTS1 expression was examined with 
anti-ADAMTS1 antibody (used at 1:100 dilution)(A-19; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) in tumor tissue transfected with 
full ADAMTS1.  (B), Tumor tissue transfected with empty vector and 
stained with anti-ADAMTS1 antibody.  (C), Tumor tissue transfected 
with delta ADAMTS1 and stained with anti-FLAG antibody.  (D), 
Tumor tissue transfected with empty vector and stained with anti-FLAG 
antibody.   Scale bar in each panel represents 100 mm. 
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